Astronics Corporation's $150M note offering led to a 15% drop in stock price. Find out why ATRO stock remains a buy with ...

Axsome Therapeutics (AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy has met its primary endpoint. Read more here.

The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.